Figure 2.

Progression of large metastatic pulmonary myxofibrosarcoma mass on computed tomography scans without contrast. (A): Depicting progression of disease after two cycles of trabectedin with 11.4 × 9.7 cm mass extending through the chest wall. (B): After two cycles of temozolomide (TMZ) with marked decrease in soft tissue component of lesion. (C): Recurrence of disease after 43 cycles of TMZ with a 7.6 × 1.8 × 4.4 cm mass resulting in destruction of adjacent ribs. (D): Stable to slightly decreased size of pulmonary mass after 16 cycles of atezolizumab.